Pasar al contenido principal

Caracterización estructural y funcional de la vía visual anterior en pacientes con esclerosis múltiple temprana (VISIONEM)

PI22/01589

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i en Salud
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON
Centro realización FUNDACION INSTITUTO DE INVESTIGACION VALLE DE HEBRON

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The OSCAR-MP Consensus Criteria for Quality Assessment of Retinal Optical Coherence Tomography Angiography

  • Wicklein, Rebecca|||0000-0002-6661-6081
  • Yam, Charmaine
  • Noll, Christina
  • Aly, Lilian|||0000-0002-7051-124X
  • Banze, Nicolas
  • Romahn, Eva Feodora
  • Wolf, Elisabeth
  • Hemmer, Bernhard|||0000-0001-5985-6784
  • Oertel, Frederike Cosima|||0000-0003-4906-5983
  • Zimmermann, Hanna G.|||0000-0002-0276-8051
  • Albrecht, Philipp|||0000-0001-7987-658X
  • Ringelstein, Marius|||0000-0003-3618-8407
  • Baumann, Carmen
  • Feucht, Nikolaus
  • Penkava, Josef
  • Havla, Joachim|||0000-0002-4386-1340
  • Gernert, Jonathan A.
  • Mardin, Christian
  • Vasileiou, Eleni S.|||0000-0002-8639-8405
  • van der Walt, Anneke|||0000-0002-4278-7003
  • Al-Louzi, Omar|||0000-0003-2260-5660
  • Cabello, Sergio
  • Vidal-Jordana, Angela|||0000-0002-7270-5507
  • Krämer, Julia
  • Wiendl, Heinz|||0000-0003-4310-3432
  • Preiningerova, Jana Lizrova|||0000-0003-0337-3462
  • Ciccarelli, Olga|||0000-0001-7485-1367
  • Garcia-Martin, Elena|||0000-0001-6258-2489
  • Kana, Veronika
  • Calabresi, Peter A.|||0000-0002-7776-6472
  • Paul, Friedemann|||0000-0002-6378-0070
  • Saidha, Shiv|||0000-0001-6387-0714
  • Petzold, Axel|||0000-0002-0344-9749
  • Toosy, Ahmed T.|||0000-0002-4441-3750
  • Knier, Benjamin|||0000-0003-4187-9472
Optical coherence tomography angiography (OCTA) is a noninvasive high-resolution imaging technique for assessing the retinal vasculature and is increasingly used in various ophthalmologic, neuro-ophthalmologic, and neurologic diseases. To date, there are no validated consensus criteria for quality control (QC) of OCTA. Our study aimed to develop criteria for OCTA quality assessment. To establish criteria through (1) extensive literature review on OCTA artifacts and image quality to generate standardized and easy-to-apply OCTA QC criteria, (2) application of OCTA QC criteria to evaluate interrater agreement, (3) identification of reasons for interrater disagreement, revision of OCTA QC criteria, development of OCTA QC scoring guide and training set, and (4) validation of QC criteria in an international, interdisciplinary multicenter study. We identified 7 major aspects that affect OCTA quality: (O) obvious problems, (S) signal strength, (C) centration, (A) algorithm failure, (R) retinal pathology, (M) motion artifacts, and (P) projection artifacts. Seven independent raters applied the OSCAR-MP criteria to a set of 40 OCTA scans from people with MS, Sjogren syndrome, and uveitis and healthy individuals. The interrater kappa was substantial (κ 0.67). Projection artifacts were the main reason for interrater disagreement. Because artifacts can affect only parts of OCTA images, we agreed that prior definition of a specific region of interest (ROI) is crucial for subsequent OCTA quality assessment. To enhance artifact recognition and interrater agreement on reduced image quality, we designed a scoring guide and OCTA training set. Using these educational tools, 23 raters from 14 different centers reached an almost perfect agreement (κ 0.92) for the rejection of poor-quality OCTA images using the OSCAR-MP criteria. We propose a 3-step approach for standardized quality control: (1) To define a specific ROI, (2) to assess the occurrence of OCTA artifacts according to the OSCAR-MP criteria, and (3) to evaluate OCTA quality based on the occurrence of different artifacts within the ROI. OSCAR-MP OCTA QC criteria achieved high interrater agreement in an international multicenter study and is a promising QC protocol for application in the context of future clinical trials and studies.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis

  • Ciccarelli, Olga
  • Calabrese, Massimiliano
  • De Stefano, Nicola
  • Eshaghi, Arman
  • Filippi, Massimo
  • Barkhof, Frederik
  • Rovira, Alex
  • Sastre Garriga, Jaume
  • TUR, CARMEN
Relapse; Pathobiological foundations; Multiple sclerosis, Recaída; Fundamentos patobiológicos; Esclerosis múltiple, Recaiguda; Fonaments patobiològics; Esclerosi múltiple, Progression independent of relapse activity (PIRA), a recent concept to formalize disability accrual in multiple sclerosis (MS) independent of relapses, has gained popularity as a potential clinical trial outcome. We discuss its shortcomings and appraise the challenges of implementing it in clinical settings, experimental trials, and research. The current definition of PIRA assumes that acute inflammation, which can manifest as a relapse, and neurodegeneration, manifesting as progressive disability accrual, can be disentangled by introducing specific time windows between the onset of relapses and the observed increase in disability. The term PIRMA (progression independent of relapse and MRI activity) was recently introduced to indicate disability accrual in the absence of both clinical relapses and new brain and spinal cord MRI lesions. Assessing PIRMA in clinical practice is highly challenging because it necessitates frequent clinical assessments and brain and spinal cord MRI scans. PIRA is commonly assessed using Expanded Disability Status Scale, a scale heavily weighted toward motor disability, whereas a more granular assessment of disability deterioration, including cognitive decline, using composite measures or other tools, such as digital tools, would possess greater utility. Similarly, using PIRA as an outcome measure in randomized clinical trials is also challenging and requires methodological considerations. The underpinning pathobiology of disability accumulation, that is not associated with relapses, may encompass chronic active lesions (slowly expanding lesions and paramagnetic rim lesions), cortical lesions, brain and spinal cord atrophy, particularly in the gray matter, diffuse and focal microglial activation, persistent leptomeningeal enhancement, and white matter tract damage. We propose to use PIRA to understand the main determinant of disability accrual in observational, cohort studies, where regular MRI scans are not included, and introduce the term of "advanced-PIRMA" to investigate the contributions to disability accrual of the abovementioned processes, using conventional and advanced imaging. This is supported by the knowledge that MRI reflects the MS pathogenic mechanisms better than purely clinical descriptors. Any residual disability accrual, which remains unexplained after considering all these mechanisms with imaging, will highlight future research priorities to help complete our understanding of MS pathogenesis.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The OSCAR-MP Consensus Criteria for Quality Assessment of Retinal Optical Coherence Tomography Angiography

  • Wicklein, Rebecca
  • Yam, Charmaine
  • Noll, Christina
  • Aly, Lilian
  • Banze, Nicolas
  • Romahn, Eva Feodora
  • Cabello, Sergio
  • Vidal-Jordana, Angela
Consensus; Angiography; Retina, Consenso; Angiografía; Retina, Consens; Angiografia; Retina, Background and Objectives Optical coherence tomography angiography (OCTA) is a noninvasive high-resolution imaging technique for assessing the retinal vasculature and is increasingly used in various ophthalmologic, neuro-ophthalmologic, and neurologic diseases. To date, there are no validated consensus criteria for quality control (QC) of OCTA. Our study aimed to develop criteria for OCTA quality assessment. Methods To establish criteria through (1) extensive literature review on OCTA artifacts and image quality to generate standardized and easy-to-apply OCTA QC criteria, (2) application of OCTA QC criteria to evaluate interrater agreement, (3) identification of reasons for interrater disagreement, revision of OCTA QC criteria, development of OCTA QC scoring guide and training set, and (4) validation of QC criteria in an international, interdisciplinary multicenter study. Results We identified 7 major aspects that affect OCTA quality: (O) obvious problems, (S) signal strength, (C) centration, (A) algorithm failure, (R) retinal pathology, (M) motion artifacts, and (P) projection artifacts. Seven independent raters applied the OSCAR-MP criteria to a set of 40 OCTA scans from people with MS, Sjogren syndrome, and uveitis and healthy individuals. The interrater kappa was substantial (κ 0.67). Projection artifacts were the main reason for interrater disagreement. Because artifacts can affect only parts of OCTA images, we agreed that prior definition of a specific region of interest (ROI) is crucial for subsequent OCTA quality assessment. To enhance artifact recognition and interrater agreement on reduced image quality, we designed a scoring guide and OCTA training set. Using these educational tools, 23 raters from 14 different centers reached an almost perfect agreement (κ 0.92) for the rejection of poor-quality OCTA images using the OSCAR-MP criteria. Discussion We propose a 3-step approach for standardized quality control: (1) To define a specific ROI, (2) to assess the occurrence of OCTA artifacts according to the OSCAR-MP criteria, and (3) to evaluate OCTA quality based on the occurrence of different artifacts within the ROI. OSCAR-MP OCTA QC criteria achieved high interrater agreement in an international multicenter study and is a promising QC protocol for application in the context of future clinical trials and studies., R. Wicklein received an intramural research grant from the Technical University of Munich, School of Medicine, and was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC-2145 - SyNergy ID 390857198). C. Yam's PhD fellowship is funded by the UCL Queen Square Institute of Neurology and Cleveland Clinic London PhD Neuroscience Fellowship. C. Noll received a research scholarship from the Gemeinnützige Hertie Foundation. L. Aly received travel and research support by Novartis. N. Banze received no funding. E. Feodora Romahn received no funding. E. Wolf received no funding. Bernhard Hemmer received funding for the study by the European Union's Horizon 2020 Research and Innovation Program [grant MultipleMS, EU RIA 733161] and the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology [EXC 2145 SyNergy - ID 390857198]. F.C. Oertel received research support by the National MS Society, American Academy of Neurology and Hertie foundation, all outside of the submitted work. H.G. Zimmermann received intramural funding from the Berlin Center for Translational Vascular Biomedicine (VasBioBerlin). P. Albrecht received no funding. M. Ringelstein received no funding. C. Baumann has no financial disclosures and no conflicting relationship. N. Feucht received no funding. J. Penkava received no funding. J. Havla reports grants from the Friedrich-Baur-Stiftung, Merck, and Horizon. C. Mardin is a medical advisor to Heidelberg Engineering, Heidelberg, Germany, receives lecture honorarium by Heidelberg Engineering, Bayer AG, Leverkusen, Germany, and is partially funded by Federal Ministry of Education and Research and Bavarian Ministry of Health. J.A. Gernert received a research grant from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation; SFB/TRR 274, ID 408885537). E. Vasileiou did not receive any funding. A. van der Walt did not receive any funding. O. Al-Louzi did not receive any funding. S. Cabello did not receive any funding. A. Vidal-Jordana has received support for contracts Juan Rodes (JR16/00024) and from Fondo de Investigación en Salud (PI17/02162 and PI22/01589) from Instituto de Salud Carlos III, Spain. J. Krämer did not receive any funding. Heinz Wiendl did not receive any funding. J.L. Preiningerova was funded by Charles University Cooperation Program in Neuroscience, and General University Hospital in Prague project MH CZ-DRO-VFN64165…. O. Ciccarelli was funded by NIHR RP-2017-08-ST2-004 and supported by researchers at the National Institute for Health and Care Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Center (BRC) including OC. E. Garcia-Martin received grant support: PI20/00437 (Carlos III Health Institute) and Inflammatory Disease Network (RICORS) (RD21/0002/0050) (Carlos III Health Institute). V. Kana received funding from the Swiss National Foundation and a Filling the Gap protected research time grant (University of Zurich), all outside of the submitted work. P.A. Calabresi reports no funding. F. Paul reports no funding. S. Saidha reports no funding. A. Petzold reports no funding. A. Toosy is supported by recent awards from the MRC (MR/S026088/1), NIHR BRC (541/CAP/OC/818837) and RoseTrees Trust (A1332 and PGL21/10079), and MSIF. B. Knier was funded by the Else Kröner-Fresenius-Stiftung (Else Kröner-Fresenius Exzellenzstipendium 2019_EKES.09) and the Gemeinnützige Hertie Foundation (medMS program) and received a research award from Novartis.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The presence of a paramagnetic phase rim in multiple sclerosis is linked to lesion age: An exploratory study

  • Klistorner, Samuel
  • Usnich, Tatiana
  • Clarke, Margareta Anna
  • paul, friedemann
  • Pareto, Deborah
  • Rovira, Alex
Chronic active lesions; Iron deposition; Lesion evolution, Lesions cròniques actives; Deposició de ferro; Evolució de la lesió, Lesiones crónicas activas; Deposición de hierro; Evolución de la lesión, Background: In relapsing-remitting multiple sclerosis (RRMS), smouldering inflammation at the rims of chronic active lesions is increasingly recognised as a key driver of disease progression. Paramagnetic rim lesions (PRLs), detected using susceptibility-weighted imaging, have emerged as a potential biomarker of this chronic inflammatory activity. However, their clinical relevance and relationship to lesion-specific features such as size and age remain poorly understood. Objective: To investigate the association between PRL presence and clinical/radiological measures of disease progression, and to explore how PRLs relate to lesion size and age. Methods: A retrospective study of 60 RRMS patients with over 5 years of magnetic resonance imaging data was conducted using susceptibility-weighted angiography. Lesions larger than 100 mm3 were analysed. Results: PRLs were present in 48% of patients and represented 13% of lesions. PRLs were significantly larger and more structurally damaged, with volume correlating with EDSS change and brain atrophy. All lesions formed within 5 years of imaging were PRLs. This finding was validated in two independent international cohorts. Moreover, the proportion of rim-positive lesions decreased as lesion age increased. Conclusion: PRLs are closely linked to lesion age and early development, supporting their role as a dynamic biomarker of lesion activity in multiple sclerosis., The authors disclosed receipt of the following financial support for the research, authorship and/or publication of this article: SK is the recipient of PhD scholarship from MS Research Australia. MAC is a 2023 ECTRIMS Postdoctoral Research Fellow and a recipient of the Skills Development Award from the UK MS Society. ÀR receives research support from Fondo de Investigación en Salud (PI19/00950 and PI22/01589) from Instituto de Salud Carlos III, Spain. DP receives research support from Instituto Carlos III, Spain (PI18/00823, PI22/01709) co-funded by the European Union. AK receives research support from MS Research Australia.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

The OSCAR-MP Consensus Criteria for Quality Assessment of Retinal Optical Coherence Tomography Angiography

  • Wicklein, Rebecca
  • Yam, Charmaine
  • Noll, Christina
  • Aly, Lilian
  • Banze, Nicolas
  • Romahn, Eva Feodora
  • Cabello, Sergio
  • Vidal-Jordana, Angela
Consensus; Angiography; Retina, Consenso; Angiografía; Retina, Consens; Angiografia; Retina, Background and Objectives Optical coherence tomography angiography (OCTA) is a noninvasive high-resolution imaging technique for assessing the retinal vasculature and is increasingly used in various ophthalmologic, neuro-ophthalmologic, and neurologic diseases. To date, there are no validated consensus criteria for quality control (QC) of OCTA. Our study aimed to develop criteria for OCTA quality assessment. Methods To establish criteria through (1) extensive literature review on OCTA artifacts and image quality to generate standardized and easy-to-apply OCTA QC criteria, (2) application of OCTA QC criteria to evaluate interrater agreement, (3) identification of reasons for interrater disagreement, revision of OCTA QC criteria, development of OCTA QC scoring guide and training set, and (4) validation of QC criteria in an international, interdisciplinary multicenter study. Results We identified 7 major aspects that affect OCTA quality: (O) obvious problems, (S) signal strength, (C) centration, (A) algorithm failure, (R) retinal pathology, (M) motion artifacts, and (P) projection artifacts. Seven independent raters applied the OSCAR-MP criteria to a set of 40 OCTA scans from people with MS, Sjogren syndrome, and uveitis and healthy individuals. The interrater kappa was substantial (κ 0.67). Projection artifacts were the main reason for interrater disagreement. Because artifacts can affect only parts of OCTA images, we agreed that prior definition of a specific region of interest (ROI) is crucial for subsequent OCTA quality assessment. To enhance artifact recognition and interrater agreement on reduced image quality, we designed a scoring guide and OCTA training set. Using these educational tools, 23 raters from 14 different centers reached an almost perfect agreement (κ 0.92) for the rejection of poor-quality OCTA images using the OSCAR-MP criteria. Discussion We propose a 3-step approach for standardized quality control: (1) To define a specific ROI, (2) to assess the occurrence of OCTA artifacts according to the OSCAR-MP criteria, and (3) to evaluate OCTA quality based on the occurrence of different artifacts within the ROI. OSCAR-MP OCTA QC criteria achieved high interrater agreement in an international multicenter study and is a promising QC protocol for application in the context of future clinical trials and studies., R. Wicklein received an intramural research grant from the Technical University of Munich, School of Medicine, and was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC-2145 - SyNergy ID 390857198). C. Yam's PhD fellowship is funded by the UCL Queen Square Institute of Neurology and Cleveland Clinic London PhD Neuroscience Fellowship. C. Noll received a research scholarship from the Gemeinnützige Hertie Foundation. L. Aly received travel and research support by Novartis. N. Banze received no funding. E. Feodora Romahn received no funding. E. Wolf received no funding. Bernhard Hemmer received funding for the study by the European Union's Horizon 2020 Research and Innovation Program [grant MultipleMS, EU RIA 733161] and the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology [EXC 2145 SyNergy - ID 390857198]. F.C. Oertel received research support by the National MS Society, American Academy of Neurology and Hertie foundation, all outside of the submitted work. H.G. Zimmermann received intramural funding from the Berlin Center for Translational Vascular Biomedicine (VasBioBerlin). P. Albrecht received no funding. M. Ringelstein received no funding. C. Baumann has no financial disclosures and no conflicting relationship. N. Feucht received no funding. J. Penkava received no funding. J. Havla reports grants from the Friedrich-Baur-Stiftung, Merck, and Horizon. C. Mardin is a medical advisor to Heidelberg Engineering, Heidelberg, Germany, receives lecture honorarium by Heidelberg Engineering, Bayer AG, Leverkusen, Germany, and is partially funded by Federal Ministry of Education and Research and Bavarian Ministry of Health. J.A. Gernert received a research grant from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation; SFB/TRR 274, ID 408885537). E. Vasileiou did not receive any funding. A. van der Walt did not receive any funding. O. Al-Louzi did not receive any funding. S. Cabello did not receive any funding. A. Vidal-Jordana has received support for contracts Juan Rodes (JR16/00024) and from Fondo de Investigación en Salud (PI17/02162 and PI22/01589) from Instituto de Salud Carlos III, Spain. J. Krämer did not receive any funding. Heinz Wiendl did not receive any funding. J.L. Preiningerova was funded by Charles University Cooperation Program in Neuroscience, and General University Hospital in Prague project MH CZ-DRO-VFN64165…. O. Ciccarelli was funded by NIHR RP-2017-08-ST2-004 and supported by researchers at the National Institute for Health and Care Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Center (BRC) including OC. E. Garcia-Martin received grant support: PI20/00437 (Carlos III Health Institute) and Inflammatory Disease Network (RICORS) (RD21/0002/0050) (Carlos III Health Institute). V. Kana received funding from the Swiss National Foundation and a Filling the Gap protected research time grant (University of Zurich), all outside of the submitted work. P.A. Calabresi reports no funding. F. Paul reports no funding. S. Saidha reports no funding. A. Petzold reports no funding. A. Toosy is supported by recent awards from the MRC (MR/S026088/1), NIHR BRC (541/CAP/OC/818837) and RoseTrees Trust (A1332 and PGL21/10079), and MSIF. B. Knier was funded by the Else Kröner-Fresenius-Stiftung (Else Kröner-Fresenius Exzellenzstipendium 2019_EKES.09) and the Gemeinnützige Hertie Foundation (medMS program) and received a research award from Novartis.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis

  • Ciccarelli, Olga
  • Calabrese, Massimiliano
  • De Stefano, Nicola
  • Eshaghi, Arman
  • Filippi, Massimo
  • Barkhof, Frederik
  • Rovira, Alex
  • Sastre Garriga, Jaume
  • TUR, CARMEN
Relapse; Pathobiological foundations; Multiple sclerosis, Recaída; Fundamentos patobiológicos; Esclerosis múltiple, Recaiguda; Fonaments patobiològics; Esclerosi múltiple, Progression independent of relapse activity (PIRA), a recent concept to formalize disability accrual in multiple sclerosis (MS) independent of relapses, has gained popularity as a potential clinical trial outcome. We discuss its shortcomings and appraise the challenges of implementing it in clinical settings, experimental trials, and research. The current definition of PIRA assumes that acute inflammation, which can manifest as a relapse, and neurodegeneration, manifesting as progressive disability accrual, can be disentangled by introducing specific time windows between the onset of relapses and the observed increase in disability. The term PIRMA (progression independent of relapse and MRI activity) was recently introduced to indicate disability accrual in the absence of both clinical relapses and new brain and spinal cord MRI lesions. Assessing PIRMA in clinical practice is highly challenging because it necessitates frequent clinical assessments and brain and spinal cord MRI scans. PIRA is commonly assessed using Expanded Disability Status Scale, a scale heavily weighted toward motor disability, whereas a more granular assessment of disability deterioration, including cognitive decline, using composite measures or other tools, such as digital tools, would possess greater utility. Similarly, using PIRA as an outcome measure in randomized clinical trials is also challenging and requires methodological considerations. The underpinning pathobiology of disability accumulation, that is not associated with relapses, may encompass chronic active lesions (slowly expanding lesions and paramagnetic rim lesions), cortical lesions, brain and spinal cord atrophy, particularly in the gray matter, diffuse and focal microglial activation, persistent leptomeningeal enhancement, and white matter tract damage. We propose to use PIRA to understand the main determinant of disability accrual in observational, cohort studies, where regular MRI scans are not included, and introduce the term of "advanced-PIRMA" to investigate the contributions to disability accrual of the abovementioned processes, using conventional and advanced imaging. This is supported by the knowledge that MRI reflects the MS pathogenic mechanisms better than purely clinical descriptors. Any residual disability accrual, which remains unexplained after considering all these mechanisms with imaging, will highlight future research priorities to help complete our understanding of MS pathogenesis.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

The presence of a paramagnetic phase rim in multiple sclerosis is linked to lesion age: An exploratory study

  • Klistorner, Samuel
  • Usnich, Tatiana
  • Clarke, Margareta Anna
  • paul, friedemann
  • Pareto, Deborah
  • Rovira, Alex
Chronic active lesions; Iron deposition; Lesion evolution, Lesions cròniques actives; Deposició de ferro; Evolució de la lesió, Lesiones crónicas activas; Deposición de hierro; Evolución de la lesión, Background: In relapsing-remitting multiple sclerosis (RRMS), smouldering inflammation at the rims of chronic active lesions is increasingly recognised as a key driver of disease progression. Paramagnetic rim lesions (PRLs), detected using susceptibility-weighted imaging, have emerged as a potential biomarker of this chronic inflammatory activity. However, their clinical relevance and relationship to lesion-specific features such as size and age remain poorly understood. Objective: To investigate the association between PRL presence and clinical/radiological measures of disease progression, and to explore how PRLs relate to lesion size and age. Methods: A retrospective study of 60 RRMS patients with over 5 years of magnetic resonance imaging data was conducted using susceptibility-weighted angiography. Lesions larger than 100 mm3 were analysed. Results: PRLs were present in 48% of patients and represented 13% of lesions. PRLs were significantly larger and more structurally damaged, with volume correlating with EDSS change and brain atrophy. All lesions formed within 5 years of imaging were PRLs. This finding was validated in two independent international cohorts. Moreover, the proportion of rim-positive lesions decreased as lesion age increased. Conclusion: PRLs are closely linked to lesion age and early development, supporting their role as a dynamic biomarker of lesion activity in multiple sclerosis., The authors disclosed receipt of the following financial support for the research, authorship and/or publication of this article: SK is the recipient of PhD scholarship from MS Research Australia. MAC is a 2023 ECTRIMS Postdoctoral Research Fellow and a recipient of the Skills Development Award from the UK MS Society. ÀR receives research support from Fondo de Investigación en Salud (PI19/00950 and PI22/01589) from Instituto de Salud Carlos III, Spain. DP receives research support from Instituto Carlos III, Spain (PI18/00823, PI22/01709) co-funded by the European Union. AK receives research support from MS Research Australia.